Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 61, Issue 10, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00777-17
Keywords
aztreonam; S. maltophilia; avibactam
Categories
Funding
- Cleveland Department of Veterans Affairs
- Veterans Affairs Merit Review Program from the U.S. Department of Veterans Affairs Biomedical Laboratory Research and Development Service of the VA Office of Research and Development [BX002872, BX001974]
- Geriatric Research Education and Clinical Center VISN [10]
- National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R21AI114508, R01AI100560, R01AI063517, R01AI072219]
- Cystic Fibrosis Foundation
Ask authors/readers for more resources
Stenotrophomonas maltophilia is an emerging opportunistic pathogen, classified by the World Health Organization as one of the leading multidrug-resistant organisms in hospital settings. The need to discover novel compounds and/or combination therapies for S. maltophilia is urgent. We demonstrate the in vitro efficacy of aztreonam-avibactam (ATM-AVI) against S. maltophilia and kinetically characterize the inhibition of the L2 beta-lactamase by avibactam. ATM-AVI overcomes aztreonam resistance in selected clinical strains of S. maltophilia, addressing an unmet medical need.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
